ArticleGland surgery2026
Novel triple-drug regimen for preoperative optimization in giant Graves' disease: a prospective efficacy and safety trial.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Graves' disease (GD) is a major cause of hyperthyroidism worldwide. Although most patients with GD achieve remission following treatment with anti-thyroid drugs (ATDs) or radioiodine ( Methods: Thirteen patients with "giant" GD scheduled for total thyroidectomy were treated with methimazole (MMI) followed by combined MMI and levothyroxine (LT4) to achieve euthyroidism. After the surgical date was scheduled, an oral compound iodine solution was administered at three drops per dose three times daily on day 1, with the dose increased by one drop per administration on each subsequent day (e.g., four drops three times daily on day 2, five drops three times daily on day 3), ultimately reaching 16 drops per dose. Primary outcome was euthyroidism [normal free thyroxine (FT4), free triiodothyronine (FT3), and thyroid-stimulating hormone (TSH) levels] at surgery. Secondary outcomes included changes in thyroid volume, superior thyroid artery peak systolic velocity (PSV), clinical parameters, operative blood loss, complications, and drug-related adverse events. Results: A total of 13 patients (9 women and 4 men), aged 19-78 years, were enrolled. The median baseline thyroid volume was 307.66 mL, which decreased to 283.68 mL following preoperative preparation. The PSV of the superior thyroid artery showed a marked reduction in all patients, ranging from 1.78% to 63.64%. Thyroid hormone levels also declined, with FT4 decreasing from 21.5-(>100) to 12.37-19.3 pmol/L and FT3 from 8.02-31.8 to 4.10-7.46 pmol/L. Basal metabolic rate (BMR) decreased from 28-60% to -11% to 16%. The operative time ranged from 120 to 270 minutes, and the median intraoperative blood loss was 77.7 mL. Significant improvement was observed in symptoms of severe hyperthyroidism, and partial relief was noted in selected extrathyroidal manifestations. Conclusions: These findings demonstrate the clinical efficacy and safety of a triple-drug preoperative preparation regimen in patients with "giant" GD. This strategy effectively reduces surgical difficulty and perioperative risk, contributing to safer and more efficient management. Incorporation of this regimen into preoperative protocols for "giant" GD may help optimize patient outcomes and surgical success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.